Cefdinir microbiology: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
mNo edit summary
 
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Cefdinir}}
{{Cefdinir}}
{{CMG}}
{{CMG}}; {{AE}} {{SS}}


==Cefdinir microbiology==
==Microbiology==
As with other [[cephalosporins]], bactericidal activity of cefdinir results from inhibition of cell wall synthesis. Cefdinir is stable in the presence of some, but not all [[Beta-lactamase|β-lactamase enzymes]]. As a result, many organisms resistant to [[penicillin]]s and some [[cephalosporins]] are susceptible to cefdinir.
 
As with other [[cephalosporins]], bactericidal activity of cefdinir results from inhibition of cell wall synthesis. Cefdinir is stable in the presence of some, but not all [[Beta-lactamase|β-lactamase enzymes]]. As a result, many organisms resistant to [[penicillins]] and some [[cephalosporins]] are susceptible to cefdinir.


Cefdinir has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in INDICATIONS AND USAGE.
Cefdinir has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in INDICATIONS AND USAGE.


====Aerobic Gram-Positive Microorganisms====
====Aerobic Gram-Positive Microorganisms====
* [[Staphylococcus aureus]] (including [[Beta-lactamase|β-lactamase enzymes]] producing strains)
* [[Staphylococcus aureus]] (including [[Beta-lactamase|β-lactamase enzymes]] producing strains)
* [[Streptococcus pneumoniae]] ([[penicillin]]-susceptible strains only)
* [[Streptococcus pneumoniae]] (penicillin-susceptible strains only)
* [[Streptococcus pyogenes]]
* [[Streptococcus pyogenes]]


Line 16: Line 18:


====Aerobic Gram-Negative Microorganisms====
====Aerobic Gram-Negative Microorganisms====
*[[Haemophilus influenzae]] (including [[Beta-lactamase|β-lactamase enzymes]] producing strains)
*[[Haemophilus influenzae]] (including [[Beta-lactamase|β-lactamase enzymes]] producing strains)
*[[Haemophilus parainfluenzae]] (including [[Beta-lactamase|β-lactamase enzymes]] producing strains)
*[[Haemophilus parainfluenzae]] (including [[Beta-lactamase|β-lactamase enzymes]] producing strains)
Line 25: Line 28:


====Aerobic Gram-Positive Microorganisms====
====Aerobic Gram-Positive Microorganisms====
* [[Staphylococcus epidermidis]] (methicillin-susceptible strains only)
* [[Staphylococcus epidermidis]] (methicillin-susceptible strains only)
* [[Streptococcus agalactiae]]
* [[Streptococcus agalactiae]]
Line 32: Line 36:


====Aerobic Gram-Negative Microorganisms====
====Aerobic Gram-Negative Microorganisms====
*[[Citrobacter diversus]]
*[[Citrobacter diversus]]
*[[Escherichia coli]]
*[[Escherichia coli]]
Line 40: Line 45:


===Susceptibility Tests===
===Susceptibility Tests===
Dilution Techniques: Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method(1) (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of cefdinir powder. The MIC values should be interpreted according to the following criteria:
Dilution Techniques: Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method(1) (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of cefdinir powder. The MIC values should be interpreted according to the following criteria:


Line 49: Line 55:


====For Streptococcus spp.====
====For Streptococcus spp.====
Streptococcus pneumoniae that are susceptible to [[penicillin]] (MIC ≤0.06 mcg/mL), or streptococci other than S. pneumoniae that are susceptible to [[penicillin]] (MIC ≤0.12 mcg/mL), can be considered susceptible to cefdinir. Testing of cefdinir against [[[[penicillin]]]]-intermediate or [[[[penicillin]]]]-resistant isolates is not recommended. Reliable interpretive criteria for cefdinir are not available.
 
Streptococcus pneumoniae that are susceptible to penicillin (MIC ≤0.06 mcg/mL), or streptococci other than S. pneumoniae that are susceptible to penicillin (MIC ≤0.12 mcg/mL), can be considered susceptible to cefdinir. Testing of cefdinir against penicillin-intermediate or penicillin-resistant isolates is not recommended. Reliable interpretive criteria for cefdinir are not available.


A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentration usually achievable. A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.
A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentration usually achievable. A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.
Line 72: Line 79:


====For Streptococcus spp.====
====For Streptococcus spp.====
Isolates of [[Streptococcus pneumoniae]] should be tested against a 1 mcg [[oxacillin]] disk. Isolates with oxacillin zone sizes ≥20 mm are susceptible to [[[[penicillin]]]] and can be considered susceptible to cefdinir. Streptococci other than S. pneumoniae should be tested with a 10 unit [[[[penicillin]]]] disk. Isolates with [[penicillin]] zone sizes ≥28 mm are susceptible to [[penicillin]] and can be considered susceptible to cefdinir.
 
Isolates of [[Streptococcus pneumoniae]] should be tested against a 1 mcg [[oxacillin]] disk. Isolates with oxacillin zone sizes ≥20 mm are susceptible to penicillin and can be considered susceptible to cefdinir. Streptococci other than S. pneumoniae should be tested with a 10 unit penicillin disk. Isolates with penicillin zone sizes ≥28 mm are susceptible to penicillin and can be considered susceptible to cefdinir.


As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms to control the technical aspects of laboratory procedures. For the diffusion technique, the 5 mcg cefdinir disk should provide the following zone diameters in these laboratory quality control strains:<ref>{{Cite web | last = |first = |title = http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/50739S2LBL.pdf |url =http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/50739S2LBL.pdf |publisher = |date = | accessdate = }}</ref>
As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms to control the technical aspects of laboratory procedures. For the diffusion technique, the 5 mcg cefdinir disk should provide the following zone diameters in these laboratory quality control strains:<ref>{{Cite web | last = |first = |title = http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/50739S2LBL.pdf |url =http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/50739S2LBL.pdf |publisher = |date = | accessdate = }}</ref>

Latest revision as of 00:51, 6 January 2014

Cefdinir
OMNICEF® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings
Precautions
Adverse Reactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Microbiology

As with other cephalosporins, bactericidal activity of cefdinir results from inhibition of cell wall synthesis. Cefdinir is stable in the presence of some, but not all β-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins are susceptible to cefdinir.

Cefdinir has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in INDICATIONS AND USAGE.

Aerobic Gram-Positive Microorganisms

NOTE: Cefdinir is inactive against methicillin-resistant staphylococci.

Aerobic Gram-Negative Microorganisms

The following in vitro data are available, but their clinical significance is unknown.

Cefdinir exhibits in vitro minimum inhibitory concentrations (MICs) of 1 mcg/mL or less against (≥90%) strains of the following microorganisms; however, the safety and effectiveness of cefdinir in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled clinical trials.

Aerobic Gram-Positive Microorganisms

NOTE: Cefdinir is inactive against Enterococcus and methicillin-resistant Staphylococcus species.

Aerobic Gram-Negative Microorganisms

NOTE: Cefdinir is inactive against Pseudomonas and Enterobacter species.

Susceptibility Tests

Dilution Techniques: Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method(1) (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of cefdinir powder. The MIC values should be interpreted according to the following criteria:

For Streptococcus spp.

Streptococcus pneumoniae that are susceptible to penicillin (MIC ≤0.06 mcg/mL), or streptococci other than S. pneumoniae that are susceptible to penicillin (MIC ≤0.12 mcg/mL), can be considered susceptible to cefdinir. Testing of cefdinir against penicillin-intermediate or penicillin-resistant isolates is not recommended. Reliable interpretive criteria for cefdinir are not available.

A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentration usually achievable. A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.

Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of laboratory procedures. Standard cefdinir powder should provide the following MIC values:

Diffusion Techniques: Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure(2) requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 5 mcg cefdinir to test the susceptibility of microorganisms to cefdinir.

Reports from the laboratory providing results of the standard single-disk susceptibility test with a 5 mcg cefdinir disk should be interpreted according to the following criteria:

For Streptococcus spp.

Isolates of Streptococcus pneumoniae should be tested against a 1 mcg oxacillin disk. Isolates with oxacillin zone sizes ≥20 mm are susceptible to penicillin and can be considered susceptible to cefdinir. Streptococci other than S. pneumoniae should be tested with a 10 unit penicillin disk. Isolates with penicillin zone sizes ≥28 mm are susceptible to penicillin and can be considered susceptible to cefdinir.

As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms to control the technical aspects of laboratory procedures. For the diffusion technique, the 5 mcg cefdinir disk should provide the following zone diameters in these laboratory quality control strains:[1]

References

  1. "http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/50739S2LBL.pdf" (PDF). External link in |title= (help)

Adapted from the FDA Package Insert.